StudyFinder

VX21-522-001: A Phase 1 Multiple Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

Status: Recruiting

This is a clinical research study exploring the safety and tolerability of a single dose of VX-522 for people with cystic fibrosis (CF) who are not expected to benefit from CFTR modulators.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 65 years old
• Stable cystic fibrosis disease
• FEV1 at least 40%
• Specific CFTR gene mutations
Exclusion Criteria:

• Uncontrolled asthma in the last year
• Oxygen saturation without oxygen therapy is >94%
• Severe liver disease
Conditions:

Rare Diseases, Breathing, Lung & Sleep Health

Keywords:

Cystic Fibrosis, CF

Study Contact: Mary Bailey - mpbailey@umn.edu
Principal Investigator: Joanne Billings
Phase: PHASE1
IRB Number: SITE00001585
See this study on ClinicalTrials.gov

Back